David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley acquired 40,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were acquired at an average cost of C$1.88 per share, for a total transaction of C$75,072.00.

Cardiol Therapeutics Price Performance

Cardiol Therapeutics stock opened at C$1.95 on Wednesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 6.84 and a current ratio of 2.39. Cardiol Therapeutics Inc. has a one year low of C$1.07 and a one year high of C$4.26. The company has a market cap of C$136.27 million, a P/E ratio of -4.43 and a beta of 0.70. The business has a fifty day moving average of C$2.41 and a two-hundred day moving average of C$2.73.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.